Seegene's three-pronged strategy includes the following:

• Mass testing with the company's MDx system at various facilities including schools, airports, workplaces, and others
• Centralized screening with the company's new diagnostic test, which Seegene says can multiply the test capacity without additional instrument investments in laboratories
• Testing for patients with respiratory symptoms

Seegene offers the Allplex RV Master Assay, which the company says can differentiate 10 targets at the same time, including COVID-19, flu, and common respiratory viruses.

The MDx platform uses artificial intelligence and allows platform users, regardless of knowledge and experience in MDx, to develop real-time polymerase chain reaction (PCR) assays.

Seegene launches automated PCR testing unit at AACC 2021
Molecular diagnostics developer Seegene is launching a new, automated, real-time polymerase chain reaction (PCR) system called STARlet-AIOS: All-in-One...

Seegene unveils SARS-CoV-2 variant detection test
Seegene has launched its Allplex SARS-CoV-2 Variants II Assay, a multiplex polymerase chain reaction test kit that can screen for six SARS-CoV-2 variants...

Bio-Rad partners with Seegene
Bio-Rad Laboratories announced a partnership with South Korean molecular diagnostics company Seegene to develop and commercialize new diagnostic products...

FDA grants emergency authorization for Seegene COVID-19 test
South Korean firm Seegene has received emergency use authorization from the U.S. Food and Drug Administration (FDA) for its Allplex COVID-19 assay.

Health Canada approves Seegene COVID-19 assay
South Korean firm Seegene has secured Health Canada approval for its Allplex 2019-nCoV assay, a real-time reverse transcription polymerase chain reaction...